SG11201811160XA - Treatment for myopia - Google Patents
Treatment for myopiaInfo
- Publication number
- SG11201811160XA SG11201811160XA SG11201811160XA SG11201811160XA SG11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- myopia
- pct
- new south
- south wales
- Prior art date
Links
- 230000004379 myopia Effects 0.000 title abstract 3
- 208000001491 myopia Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 2
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 abstract 2
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 229930064664 L-arginine Natural products 0.000 abstract 1
- 235000014852 L-arginine Nutrition 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004423 myopia development Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIP0 I PCT Iiiimmomiolollmolomm VIII iflo Hs (10) International Publication Number WO 2017/219080 Al 1-1 GC 1-1 N 1-1 O O (51) International Patent Classification: A61K 31/198 (2006.01) A61P 27/02 (2006.01) A61K 31/04 (2006.01) (21) International Application Number: PCT/AU2017/050627 (22) International Filing Date: 21 June 2017 (21.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016902429 21 June 2016 (21.06.2016) AU (71) Applicant: THE UNIVERSITY OF NEWCASTLE [AU/AU]; 130 University Drive, Callaghan, New South Wales 2308 (AU). (72) Inventor: MCFADDEN, Sally Anne; 56 Dawson Street, Cooks Hill, New South Wales 2300 (AU). (74) Agent: DAVIES COLLISON CAVE PTY LTD; 255 Elizabeth Street, Sydney, New South Wales 2000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) = (54) Title: TREATMENT FOR MYOPIA FIGURE 1 A B Diffe re nce in Refrac t ive Erro r ( D) Diffe re nce in Ocu la Le r ng t h (p. m) 150 100 50 0 -50 - 100 - 150 -6D Plano Rec -6D Plano Rec (57) : Provided herein are methods for treating or preventing myopia, or for inhibiting the development of myopia, comprising administering to a subject in need thereof an effective amount of an agent capable of increasing nitric oxide levels in one or more ocular cells or an agent capable of promoting or increasing the expression and/or activity of nNOS in one or more ocular cells. Also provided are methods for inducing or promoting nNOS expression and/or activity in one or more ocular cells, comprising exposing said cells to an effective amount of L-arginine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016902429A AU2016902429A0 (en) | 2016-06-21 | Treatment for myopia | |
| PCT/AU2017/050627 WO2017219080A1 (en) | 2016-06-21 | 2017-06-21 | Treatment for myopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811160XA true SG11201811160XA (en) | 2019-01-30 |
Family
ID=60783610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811160XA SG11201811160XA (en) | 2016-06-21 | 2017-06-21 | Treatment for myopia |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10945980B2 (en) |
| CN (1) | CN109640973A (en) |
| SG (1) | SG11201811160XA (en) |
| WO (1) | WO2017219080A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3763280A1 (en) * | 2019-07-11 | 2021-01-13 | Carl Zeiss Vision International GmbH | Determination of a change in the refraction error of an eye |
| CN110934865A (en) * | 2019-12-06 | 2020-03-31 | 牡丹江医学院 | A kind of pharmaceutical composition for preventing and treating hypotension in hemodialysis and use thereof |
| IL298796A (en) * | 2020-06-02 | 2023-02-01 | Univ Columbia | Methods and preparations for the prevention and treatment of myopia (myopia) with levocevastine, a selective antagonist of the H1-histamine receptor, and its derivatives |
| IL299012A (en) * | 2020-06-11 | 2023-02-01 | Univ Columbia | Methods and preparations for the prevention and treatment of myopia (myopia) with S-methyl-L-thiocitrulline, a selective inhibitor of nitric oxide synthase (NNOS), and their derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000054773A1 (en) * | 1999-03-12 | 2000-09-21 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| AU779991B2 (en) | 1999-08-10 | 2005-02-24 | Board Of Regents, The University Of Texas System | Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight |
| WO2002024191A1 (en) | 2000-09-20 | 2002-03-28 | Yong Guang Pharmaceutical Co., Ltd. | Therapeutic and prophylactic drugs of myopia |
| RU2635185C2 (en) * | 2013-12-17 | 2017-11-09 | Иван Дмитриевич Захаров | Pharmaceutical preparation for prevention and treatment of progressive myopia |
-
2017
- 2017-06-21 WO PCT/AU2017/050627 patent/WO2017219080A1/en active Application Filing
- 2017-06-21 CN CN201780051455.8A patent/CN109640973A/en active Pending
- 2017-06-21 US US16/310,587 patent/US10945980B2/en active Active
- 2017-06-21 SG SG11201811160XA patent/SG11201811160XA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109640973A (en) | 2019-04-16 |
| WO2017219080A1 (en) | 2017-12-28 |
| US20190142778A1 (en) | 2019-05-16 |
| US10945980B2 (en) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201906161VA (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
| SG11201908857QA (en) | Methods for the treatment of inflammation and inflammatory conditions | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201810443SA (en) | Invasive medical devices including magnetic region and systems and methods | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201811160XA (en) | Treatment for myopia | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201809341PA (en) | Mobile robot | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201805381TA (en) | Electroporation device with detachable needle array with lock-out system | |
| SG11201809605PA (en) | Compositions for and method of treating acid-base disorders | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201809474TA (en) | Compositions and methods for bioengineered tissues |